For UK HealthTech companies
Your Series A story falls apart the moment investors ask about NHS traction
Healthcare investors run rigorous commercial due diligence, and the most common reasons raises fail are weak traction evidence, an unclear go-to-market strategy, and a commercial model that doesn't hold up to scrutiny.
Two minutes. Solva follows up with specific investor-readiness options.
- Multiple investor meetings without progressing to term sheets
- Feedback from investors consistently highlighting commercial model or NHS traction concerns
- Difficulty articulating a clear, scalable go-to-market strategy for the UK healthcare system
- Over-reliance on pilot projects without a clear path to broader adoption and revenue generation
- Diversion of significant management time and resources away from product development and core operations
- Delayed fundraising timelines, impacting runway and growth plans
- Increased burn rate due to extended fundraising periods, potentially leading to down rounds or liquidation
- Missed opportunities for strategic partnerships and market entry due to perceived commercial immaturity
- Damage to founder and company reputation within the investor community
- Difficulty attracting future investment rounds or strategic partners
No verified UK data available
Source: No verified UK data available
Frequently asked questions
Why does this problem persist?
Healthcare investors apply rigorous commercial due diligence to healthtech companies, and the most common reasons for failed raises are weak commercial traction, an unclear go-to-market strategy, and an inability to demonstrate a credible path to NHS adoption at scale. Founders who have not stress-tested their commercial model, built a pipeline of credible NHS customers, or developed a clear market access strategy are at a significant disadvantage in a competitive fundraising environment.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.